Today, lentiviral vectors are favorable vectors for RNA interference delivery in anti-HIV therapeutic approaches. Nevertheless, problems such as the specific recognition of target cells and uncontrolled expression of the transgene can restrict their use in vivo. Herein we present a new HIV-inducible promoter to express anti-HIV short hairpin RNA (shRNA) by RNA Pol II in mammalian cells. We likewise showed a novel third-generation lentiviral vector system with more safety and a specific tropism to the target cells. The new promoter, CkRhsp, was constructed from the chicken β-actin core promoter with the R region of HIV-1 long terminal repeat fused upstream of minimal hsp70 promoter. This system was induced by HIV-1 Tat, and activates transcription of two shRNAs against two conserved regions of HIV-1 transcripts produced in two steps of the virus life cycle. We also mimicked HIV-1 cell tropism by using the HIV-1 envelope in structure of third-generation lentiviral vector. The new fusion promoter efficiently expressed shRNA in a Tat-inducible manner. HIV-1 replication was inhibited in transient transfection and stable transduction assays. The new viral vector infected only CD4+cells. CkRhsp promoter may be safer than other inducible promoters for shRNA-mediated gene therapies against HIV. The use of the wild envelope in the vector packaging system may provide the specific targeting T lymphocytes and hematopoietic stem cells for anti-HIV-1 therapeutic approaches in vivo.
DeeksSG. Antiretroviral treatment of HIV infected adults. BMJ, 2006; 332:1489.
3.
PhillipsAN, GazzardBG, ClumeckN, et al.When should antiretroviral therapy for HIV be started?. BMJ, 2007; 334:76–78.
4.
LiM-J, BauerG, MichienziA, et al.Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther, 2003; 8:196–206.
5.
UnwallaHJ, RossiJJ. A dual function TAR Decoy serves as an anti-HIV siRNA delivery vehicle. Virol J, 2010; 7:33.
6.
HaasnootJ, BerkhoutB. Nucleic acids-based therapeutics in the battle against pathogenic viruses. Handb Exp Pharmacol, 2009;(189):243–263.
7.
SpurgersKB, SharkeyCM, WarfieldKL, et al.Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res, 2008; 78:26–36.
8.
BernsteinE, CaudyAA, HammondSM, et al.Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 2001; 409:363–366.
9.
ChendrimadaTP, GregoryRI, KumaraswamyE, et al.TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature, 2005; 436:740–744.
10.
CaplenNJ, ParrishS, ImaniF, et al.Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA, 2001; 98:9742–9747.
11.
LeeNS, DohjimaT, BauerG, et al.Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol, 2002; 20:500–505.
12.
XiaH, MaoQ, PaulsonHL, et al.siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol, 2002; 20:1006–1010.
13.
SachdevaG, D'CostaJ, ChoJE, et al.Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance. J Med Virol, 2007; 79:118–126.
14.
GalimiF, VermaIM. Opportunities for the use of lentiviral vectors in human gene therapy. Curr Top Microbiol Immunol, 2002; 261:245–254.
15.
HumeauLM, BinderGK, LuX, et al.Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+infected patients grouped according to CD4 count and viral load. Mol Ther, 2004; 9:902–913.
16.
SnyderLL, EsserJM, PachukCJ, et al.Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts. Antiviral Res, 2008; 80:36–44.
17.
ParkJ, NadeauPE, MergiaA. Activity of TAR in inducible inhibition of HIV replication by foamy virus vector expressing siRNAs under the control of HIV LTR. Virus Res, 2009; 140:112–120.
18.
UnwallaHJ, LiM-J, KimJD, et al.Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol, 2004; 22:1573–1578.
19.
UnwallaHJ, LiH-T, BahnerI, et al.Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol, 2006; 80:1863–1873.
20.
JeangKT, XiaoH, RichEA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem, 1999; 274:28837–28840.
21.
HanP, BrownR, BarsoumJ. Transactivation of heterologous promoters by HIV-1 tat. Nucleic Acids Res, 1991; 19:7225–7229.
22.
SanghviVR, SteelLF. Expression of interfering RNAs from an HIV-1 Tat-inducible chimeric promoter. Virus Res, 2011; 155:106–111.
23.
Ter BrakeO, KonstantinovaP, CeylanM, et al.Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther, 2006; 14:883–892.
24.
FarazmandfarT, Khanahmad ShahrezaH, HaghshenasMR, et al.Use of integrase-minus lentiviral vector for transient expression. Cell J, 2012; 14:76–81.
25.
JanbabaiG, FarazmandfarT, KhosraviS. An investigation on 10 micro RNAs in colorectal cancer as biomarkers to predict disease progression. Adv Biol Res, 2013; 7:144–119.
26.
YamPY, LiS, WuJ, et al.Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther, 2002; 5:479–484.
27.
KingstonRE, ChenCA, RoseJK. Calcium phosphate transfection. Curr Protoc Mol Biol Ed Frederick M Ausubel Al, 2003;Chapter 9:Unit 9.1.
28.
BanerjeaA, LiM-J, BauerG, et al.Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+progenitor cell-derived macrophages. Mol Ther J Am Soc Gene Ther, 2003; 8:62–71.
29.
McManusMT, SharpPA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet, 2002; 3:737–747.
30.
CouzinJ. Small RNAs make big splash. Science, 2002; 298:2296–2297.
31.
BerkhoutB. RNA interference as an antiviral approach: targeting HIV-1. Curr Opin Mol Ther, 2004; 6:141–145.
32.
Ter BrakeO, BerkhoutB. A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J RNAi Gene Silenc, 2005; 1:56–65.
33.
LeeNS, RossiJJ. Control of HIV-1 replication by RNA interference. Virus Res, 2004; 102:53–58.
34.
HaasnootPCJ, CupacD, BerkhoutB. Inhibition of virus replication by RNA interference. J Biomed Sci, 2003; 10:607–616.
35.
LeeS-K, DykxhoornDM, KumarP, et al.Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood, 2005; 106:818–826.
36.
ChangL-J, LiuX, HeJ. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Ther, 2005; 12:1133–1144.
37.
DaveRS, PomerantzRJ. Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains. J Virol, 2004; 78:13687–13696.
38.
HanW, Wind-RotoloM, KirkmanRL, et al.Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site. Virology, 2004; 330:221–232.
39.
DasAT, BrummelkampTR, WesterhoutEM, et al.Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol, 2004; 78:2601–2605.
40.
WesterhoutEM, OomsM, VinkM, et al.HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res, 2005; 33:796–804.
41.
DropulićB, HĕrmánkováM, PithaPM. A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci USA, 1996; 93:11103–11108.
42.
PaikSY, BanerjeaA, ChenCJ, et al.Defective HIV-1 provirus encoding a multitarget-ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the cells from pathogenesis. Hum Gene Ther, 1997; 8:1115–1124.
43.
GoldschmidtV, RigourdM, EhresmannC, et al.Direct and indirect contributions of RNA secondary structure elements to the initiation of HIV-1 reverse transcription. J Biol Chem, 2002; 277:43233–43242.
